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Diet is estimted to contribute to approximately 50% ofall newlydiagnosed breast cancers. As
such, asearch fordietaryfactorsdifferentially consumedamongpopulationswith increased breast
cancerrisk(e.g., Caucasians) compared to thosewithlowrisk(e.g.,Asians) has becomeapriority.
One such dietarycomponent, which is typical to theAsian but not the Caucasian diet, is soy. We
review data relevant to attempts to determine whether soy, and more specifically genistein, is a
dietary component that may help to explain the dramatic disparity in breast cancer risk among
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Epidemiologic data indicate a great disparity
between breast cancer risks in Western and
Eastern countries. Historically, the risk of
American women developing breast cancer
has been as high as 7 times that of Asian
women (1). Today the disparity in risk is
similarly significant, although the difference
in incidence between Western and Eastern
countries has narrowed slightly. For exam-
ple, one in eight white women in the United
States can expect to develop breast cancer in
her lifetime; this risk is roughly 5-fold less in
Japanese and Chinese women residing in
Asia (2). However, extensive migration stud-
ies indicate that Asian women who immi-
grate to the United States and adopt a
Western lifestyle develop risk comparable to
Caucasian women within two generations
(3,4). These studies provide strong evidence
in support of other epidemiologic studies
showing that 5-10% of breast cancer cases
are estimated to be attributable to inherited
factors, and thus > 90% ofnewly diagnosed
breast cancers may be caused by unspecified
factors probably related to lifestyle. Ziegler et
al. (5) investigated the link between age of
immigration to the United States and
increased breast cancer risk in Chinese,
Japanese, and Filipino women. The authors
found a strong correlation between early age
of immigration (< 35 years of age) and a
marked increase in breast cancer risk (5). In
fact, Asian women born in America, com-
pared to their counterparts born in the East,
had a 60% higher risk of breast cancer.
Additionally, in all three ethnic groups,
immigrants living in the United States for
more than a decade had a significantly
greater riskthan more recent immigrants (5).
It is clear from both epidemiologic and
clinical data that exposure to estrogens has
significant influences on breast cancer devel-
opment. Estrogens induce the proliferation
of normal and malignant mammary cells,
and are thus linked to breast cancer promo-
tion and progression. Interestingly, a number
of reports indicate that Asian women living
in Asia have up to roughly 40% lower serum
estrogen levels than Caucasian women living
in the United States or Britain (6,7). Based
on these data, it is increasingly clear that the
protective effect seen in Asian countries does
not correlate with genetic influences, but
rather, with environmental and lifestyle fac-
tors. Thus, it has long been the goal ofinnu-
merable scientists to isolate those factors that
may be responsible for the dramatic disparity
in breast cancer risk between Caucasian and
Asian women.
Diet is estimated to contribute to up to
50% of all newly diagnosed breast cancer
cases (8,9). One particular class of dietary
compounds that has received much atten-
tion, based on their high concentration in
potentially protective foods and their report-
ed antiproliferative effects, is phytoestrogens.
Consumption ofphytoestrogens, particularly
soy products, as well as legumes, is higher in
Asia than in the Western world (10). Soy-
based diets are high in genistein (4,5,7-trihy-
droxyisoflavone), which has been widely
studied for its potential anticancer proper-
ties. The exact mechanism by which genis-
tein may exert its antitumorigenic effects is
not clearly understood; however, it is a spe-
cific and potent inhibitor of both protein
tyrosine kinases and topoisomerase II
(11,12). Furthermore, genistein is able to
inhibit angiogenesis and metastasis in some
tumor models and to selectively reverse mul-
tidrug resistance protein-associated mul-
tidrug resistance in in vitro studies (13-15).
Recently, genistein's ability to inhibit the
cytochrome P450 enzyme CYPlAI has been
described (16). The inhibition of CYPlAI
may lead to a reduction in the production of
DNA-damaging carcinogen metabolites and
may be one mechanism by which genistein
can protect against carcinogenesis (16).
Given reports ofits antiproliferative abilities,
genistein appears to be a potentially power-
ful weapon in the breast cancer prevention
and treatment arsenal. A recent review by
Barnes (17) discussed the possible protective
role of genistein in breast cancer, However,




The phytoestrogen genistein is present natu-
rally as several 3-glucosides, which are
metabolized by intestinal microflora to
genistein (15). Genistein, a planar molecule
with an aromatic A ring, has a chemical
structure similar to steroidal estrogens,
and its ability to behave as an estrogen in
various tissues has been widely described.
Observations of phytoestrogens' estrogenic
properties date back to the 1950s, when it
was discovered that the diadezan metabolite
equol was the compound responsible for
reduced reproductive capacity in sheep graz-
ing on clover. Subsequently, countless stud-
ies have been conducted to characterize the
hormonal effects of phytoestrogens includ-
ing genistein's estrogenic and presumed
antiestrogenic properties.
Genistein has significant estrogenic prop-
erties in both in vitro and in vivo models
(Table 1). Genistein binds to the estrogen
receptor (ER), although its binding affinity is
several-fold weaker than that ofestradiol (30).
Genistein can also activate a number ofestro-
gen-responsive genes in vitro, including pS2
and c-fos (18,31). Furthermore, when admin-
istered at low doses, genistein stimulates the
growth of ER-positive (ER+) breast cancer
cells (18-20). Findings in other tissue systems
support the estrogenicity of genistein. For
example, genistein is uterotrophic in a variety
ofspecies, resulting in impaired reproductive
activity and increases in uterine wet weights
(21,25,26). It is important to note that some
studies have failed to see any effect ofgenis-
tein on the uterus, including alterations in
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Table 1. Estrogenic effects of genistein.
Observation Reference
Inhibition of CYPlA1 (16)
Stimulation of ER+ human breast (18-20)
cancer cells in vitro
Stimulation of human ER+ breast (16)
cancer cells in vivo
Stimulation of rodent mammary gland (18,21,22
Stimulation of human breast (23,24)
Stimulation of reproductive tissues (21,25,26)
Estrogenic effects on bone, (27-29)
cardiovascular system, and lipid profiles
wet weight (32,33). Furthermore, findings
with coumestrol, a more estrogenic phytoe-
strogen than genistein, indicate that although
coumestrol increases uterine wet weights, it
does not increase uterine DNA content or
alter other indicators of more true estrogenic
activity (34). Thus, an increase in uterine wet
weight alone does not necessarily indicate that
genistein has estrogenic properties.
In addition to directly binding to the ER,
genistein may indirectly affect estrogenicity
through inhibition of the cytochrome P450
enzyme CYPlAI. It has recently been shown
that genistein is a noncompetitive inhibitor
of the CYPlAI enzyme, which apart from
playing a role in the metabolism of carcino-
gens, is responsible for the metabolic degra-
dation of 17,1-estradiol. Thus, it is possible
that genistein-mediated inhibition ofestradi-
ol degradation could result in higher levels of
circulating estradiol and thus elevated ER
activity (16).
Genistein has estrogenic effects on the
hypothalamic/pituitary axis in ovariec-
tomized Sprague-Dawley rats (21). Human
studies indicate that high soy intake can dis-
rupt the hypothalamic/pituitary/gonadal axis
in premenopausal women similar to that
seen in animal models (23,35). This pertur-
bation is not seen in postmenopausal women
(36), suggesting a differential effect of
soy/genistein on pre- and postmenopausal
women. Finally, genistein may exert benefi-
cial effects on bone, cardiovasculature, and
lipid profiles, all ofwhich are effects charac-
teristic ofestrogen (27-2S9). Taken together,
these studies indicate that genistein can
behave as an estrogen and can mediate mito-
genic effects via the ER.
Estrogens have long been identified as
important mitogens in the breast and thus
are associated with an increase in breast can-
cer risk. This is evidenced by the link
between reproductive factors, including ages
of first menarche, first pregnancy, and
menopause, and breast cancer risk (37). This
is further supported by studies showing that
elevated concentrations of estrogens in
serum and urine are associated with
increased postmenopausal breast cancer risk
(38,39). Additionally, estrogens induce
mitogenic effects in both in vitroand in vivo
models of breast cancer (40). The role of
estrogen in this disease is supported by the
fact that removal of ovarian estrogens by
bilateral ovariectomy (41) or use of tamox-
ifen (which blocks ER in the mammary
gland) (42) significantly reduces breast can-
cer risk. Because estrogen exposure presum-
ably increases breast cancer risk, evidence
showing that genistein acts in an estrogenic
fashion is puzzling in light of the in vitro
reports of genistein as an anticancer agent.
To address studies that demonstrate the pro-
tective effects ofgenistein in in vitro and in
vivo breast cancer models, it is important to
determine whether genistein has antiestro-
genic properties as well.
Possible Antiestrogenic
Effects of Genistein
Genistein does not always induce prolifera-
tion ofER cells. For example, in some stud-
ies genistein exhibits an antiproliferative
effect in mammary and uterine tissues
(19,43,44). Thus, these data could be inter-
preted to indicate that genistein is acting as a
classical antiestrogen; i.e., it competitively
inhibits estrogen's binding to the ER and
transactivation of estrogen-responsive genes.
However, a more plausible explanation is
that genistein inhibits estrogenicity in some
other manner. For example, genistein may
act in an antiestrogenic fashion through its
inhibition ofestrogen-metabolizing enzymes.
In vitro studies in the human breast cancer
cell line T47D show the ability ofgenistein
to significantly inhibit the enzyme 17p-
hydroxysteroid oxidoreductase type 1
(HSOR-1) (45). HSOR-1 belongs to the
family ofshort-chain alcohol dehydrogenas-
es, which are involved in the metabolism of
steroids, antibiotics, and prostaglandins (46).
HSOR-1 is necessary for estradiol secretion
from the ovaries in premenopausal women.
Additionally, it may be essential for the
reduction of estrone to estradiol that occurs
in the adipose and other tissues (47). Thus,
inhibition of this enzyme could lead to
decreased total estradiol. In vitro studies
have also shown that isoflavones can inhibit
the aromatase enzyme, which is responsible
for the conversion of androgens to estrone
in the peripheral (adipose) tissues, although
this has not been shown with genistein
specifically (48).
The idea of genistein leading to a
decrease in estrogenicity through the inhibi-
tion ofthese estrogen-metabolizing enzymes
is in contrast to the idea that genistein may
increase estrogenicity by inhibiting CYPlAl.
On one hand, the inhibition of HSOR-1
could lead to decreased production ofestra-
diol in peripheral tissues and ovarian release
of estradiol, thus resulting in a decrease in
total estradiol, whereas inhibition of
CYPlAI could result in the opposite, lead-
ing to a buildup oftotal estradiol levels. It is
not clear, therefore, what the net effect of
genistein would be on overall estrogenicity
(Figure 1). Furthermore, in addition to
genistein's ability to inhibit the enzymatic
activity ofHSOR-1 and CYPlAl, genistein
may affect these estrogen-metabolizing
enzymes in another fashion. It is possible
that the disruptive effects ofgenistein on the
hypothalamic/pituitary/gonadal axis could
lead to an upregulation of one or more of
these enzymes, further complicating the
issue ofthe overall estrogenic effect ofgenis-
tein. However, depending on which, ifany,
of these enzymes would be upregulated in
response to a perturbation ofthe hypothala-
mic/pituitary/gonadal axis, it is possible that
the overall effect ofgenistein could be either
an increase or decrease in estrogenicity.
Thus, the overall estrogenic/antiestrogenic
effects of genistein, as a result of inhibiting
the activityofestrogen-metabolizing enzymes,
are undearandwarrantfurtherstudy.
In support of the possibility that genis-
tein may have antiestrogenic effects by
reducing circulating estrogen levels, there is
some evidence that the consumption ofhigh
levels ofsoy products decreases plasma estra-
diol concentrations in premenopausal
women (49,50). These women also had
lengthened menstrual cycles (23). However,
in some studies serum estradiol levels were
not changed (35,36,51,52) orwere increased
in women supplemented with soy (53).
Postmenopausal women did not showanyof
these effects. Perhaps the contrasting find-
ings can be partially explained by the obser-
vation that genistein reduces gonadotrophin
hormone-induced release ofluteinizing hor-
mone and follicular stimulating hormone
(54). This in turn would initially lead to a
reduction in estrogen production from the
ovaries and eventually perhaps to an increase
through a negative feedback mechanism act-
ing on the hypothalamic/pituitary/gonadal
axis (Figure 1). However, because genistein
also interferes with HSOR-1, resulting in
reduced estradiol production, and CYPlAI,
resulting in increased estradiol levels, the net
result may be either reduced or increased cir-
culating estradiol levels, perhaps depending
on the presence of additional simultaneous
estrogenic stimuli (e.g., dietaryfat).
Regardless ofan effect on the concentra-
tion ofcirculating estradiol, genistein may be
able to reduce the bioavailability ofestradiol
by increasing the synthesis of sex-hormone-
binding globulin (SHBG) through stabiliza-
tion ofSHBG mRNA in a manner analogous
to estradiol (55). SHBG binds and sequesters
hormones, thereby reducing the concentra-
tion of bioavailable or free hormone.
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However, in the presence of genistein,
increased levels ofSHBG may not necessari-
ly lead to reduced estrogenicity. It is possible
that when estradiol is bound to SHBG,
genistein is free to bind to ER, resulting in
transactivation of estrogen-responsive genes.
Furthermore, given the structural similarities
of genistein and endogenous estrogens, it is
feasible that genistein could bind to SHBG
and displace sequestered estrogens, thus
effectively increasing the concentration of
free estrogens in the body. However, studies
by Baker et al. (56) and Martin et al. (30)
show that genistein's binding affinities for
rat alpha-fetoprotein (another member of
the steroid-hormone-binding family of pro-
teins) and human SHBG are significantly
less than that ofestradiol. This evidence sug-
gests that genistein is probably not acting to
displace endogenous estrogen from its bind-
ing proteins in humans and rodents (56).
Thus, these data as a whole demonstrate that
genistein may be a modulator ofbioavailable
estrogens. However, given its potential estro-
genic activity, the cumulative effects of this
reduction in endogenous estrogens, either by
inhibiting metabolism or increasing seques-
tration, may not be significant.
Another possible antiestrogenic effect of
genistein may be its ability to alter the kinet-
ics of receptor translocation. Studies in the
MCF-7 human breast cancer cell line indi-
cate that genistein-bound ER may translo-
cate to the nucleus more slowly than
estrogen-bound ER, thus resulting in an
antiestrogen-like effect of diminished signal
transduction (30). However, this phenome-
non has not been widely studied.
It is clear that in vitro genistein competes
with estradiol for receptor binding (57).
However, because genistein binds to both
the classic ER-o and the novel ER-F recep-
tor subtypes with relative binding affinities
of roughly 20- and 5-fold less than that of
estradiol, respectively (58), it is possible that
genistein may not effectively compete with
estradiol for ER binding in vivo. Further-
more, ER-o and ER-3, when bound to
estradiol, appear to exert opposite effects on
the API transcription factor; i.e., estradiol
leads to transcriptional activation when com-
plexed with ER-o, whereas estradiol repress-
es transcription when coupled with ER-P
(59). There is some evidence to indicate that
activation of ER-P inhibits cellular prolifera-
tion. For example, several antiestrogens
behave as potent transcriptional activators
when bound to ER-F at an API site (59), and
this may explain why an inhibition of cell
growth occurs. Because genistein preferential-
ly binds toER-P, it may induce antiestrogenic
effects through this receptor isoform.
In summary, genistein may have antie-
strogenic effects through binding preferen-
tially to ER-f, by inhibiting the activity of
enzymes that participate in estrogen metabo-
lism, or by affecting the hypothalamus in an
estrogenic manner. The two latter effects can
Figure 1. Potential pathways leading to estrogenic/antiestrogenic effects of genistein.
further lead to reduced circulating estrogen
levels and increased menstrual cycle length.
These possibilities are illustrated in Figure 1




Clearly, based on the findings of studies
addressing the estrogenicity and antiestro-
genicity ofgenistein, it cannot be concluded
whether the net result ofgenistein consump-
tion will be a proliferative or antiproliferative
effect on breast cells. Many reports in the lit-
erature indicate that genistein is an inhibitor
rather than a stimulator of mammary car-
cinogenesis. These reports consist ofstudies
conducted in human breast cancer cells in
which genistein inhibits cell growth (20),
animal studies in which genistein inhibits
initiation or promotion of carcinogen-
induced mammary tumorigenesis (44,60),
and epidemiologic studies in which high
soy intake is linked to reduced breast cancer
risk (61,62). However, the literature also
contains many studies that have produced
contrasting data.
In vitro studies. Studies conducted in
human breast cancer cell lines indicate that
genistein both inhibits and stimulates prolif-
eration of these cells. For example, Hsieh et
al. (18) observed a mitogenic effect ofgenis-
tein at low doses (0.01-1 pM) and an
antiproliferative effect at higher doses
(> 10 pM). The results ofthis study are con-
sistent with the data ofWang et al. (20), in
which the growth ofMCF-7 cells was stimu-
lated and then inhibited by genistein in a
dose-dependent manner. Thus, at doses of
< 1 pM, genistein appears to stimulate the
growth of ER+ breast cancer cells (18,20).
These doses correspond to the human (physi-
ologic) exposure level because most Asians or
Caucasians that consume a high soy diet have
serum genistein levels of< 1 pM. Conversely,
doses > 10 pM genistein inhibit the growth
of both ER+ and ER-negative (ER-) breast
cancer cells (20). This strongly implicates
that the mechanisms ofinhibition ofcell pro-
liferation by pharmacologic doses ofgenistein
occur independently of the ER. It is also
apparent that at physiologic exposure levels,
Table 2. Mechanisms through which genistein
could reduce estrogenicity.
Observation Reference
Inhibition of enzymes that metabolize (45,48)
estrogens
Reduction in circulating estradiol levels (49,50)
Lengthened menstrual cycle (23)
Stimulation of sex-hormone-binding protein (55)
Preferential bindings to ER-P, leading to (58)
inhibition of AP-1 transcription (59)
Some of these findings are opposed or unconfirmed by
other data.
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it is more likely that breast cell growth is
stimulated rather than inhibited bygenistein.
Animal data. Most animal studies are
supportive ofthe hypothesis that genistein or
consumption of soy protein inhibits mam-
marytumor promotion (63-66). These find-
ings were obtained from studies in intact rats
and mice with functional ovaries that were
exposed to carcinogens to initiate tumor for-
mation. However, some studies show an
ability of genistein to increase mammary
tumorigenesis. Hsieh et al. (18) examined
the effects ofgenistein exposure on ovariec-
tomized athymic mice. Genistein, when
administered through the diet at a dose of
750 ppm, enhanced epithelial proliferation in
the mammary gland as well as the growth of
MCF-7 cell (ER+) tumors in vivo. These in
vivo results are particularly compelling
because theywere obtained in ovariectomized
mice, which may represent a model for breast
cancer development in postmenopausal
women. Thus genistein, albeit a weak estro-
gen, could have mitogenic effects on mam-
mary tissue when serum estrogen levels are
low, such as in postmenopausal women.
Human data. The estrogenic effects of
genistein/soy are not only seen in in vitro
studies or in animal models. Petrakis et al.
(23) found that 5 months ofdaily intake of
38 g soy protein isolate containing 38 mg
genistein increased the yield of nipple aspi-
rate fluid (NAF) and the appearance of
hyperplastic epithelial cells in premenopausal
women. There were no significant changes
observed in postmenopausal women (23).
Previous studies showed a reduced total vol-
ume, a lighter color, and less atypical epithe-
lial cells in the NAF obtained from women
with low breast cancer risk (i.e., Chinese and
Japanese women) compared to women with
high breast cancer risk (67-69). These stud-
ies suggest a correlation between volume,
color, and cytology ofNAF with breast can-
cer risk. In another study, 14-day daily
intake of60 g soy supplement containing 45
mg isoflavones significantly increased the
proliferative rate ofbreast lobular epithelium
in premenopausal women (24). Both of
these studies indicate that soy/genistein has
an estrogenic effect on the human breast.
Furthermore, the results obtained in the
soy/NAF/breast proliferation studies would
seem to suggest that the genistein in soy is
not acting in a protective manner in pre-
menopausal women and may have no effect
in postmenopausal women.
Caution must be exercised when inter-
preting the data of these two studies that
apparently indicate an estrogenic effect of
soy on the human breast. In particular, the
Petrakis et al. (23) study contains several
potential confounding factors. First, men-
strual cycling was not controlled for in this
study, and thus NAFs were not obtained at
the same phase of the menstrual cycle.
However, this may not have affected the
results because menstrual cycle has not been
found to affect either the hormonal or cyto-
logic content of NAF (70). Second, some
women in the study were exposed either to
oral contraceptives or hormone replacement
therapy, and this could have interacted with
the effects ofsoy on NAF. Third, all women
previouslyyielded NAF, and becauseyielders
are at a higher risk to develop breast cancer
than nonyielders (67,68), study subjects may
have been particularly sensitive to the estro-
genic effects ofgenistein in soy. Finally, it is
possible that other components ofa Western
diet may have interacted with soy adminis-
tration, producing a different outcome than
ifstudysubjects had beenAsian women con-
suming anAsian diet.
The epidemiologic evidence supporting
the idea that high soy consumption protects
against breast cancer is also inconsistent
(61). Three studies suggest that soy intake is
associated with lower breast cancer risk. A
study in Singaporean women found that
high soy intake is associated with a lower
breast cancer risk among premenopausal but
not postmenopausal women (62). A study in
Asian-American women living in the West
indicated that breast cancer risk decreases
with increasing frequency oftofu (bean curd)
intake in both pre- and postmenopausal
women (71). Finally, a study that measured
urinary excretion levels of phytoestrogens
reported that a high excretion ofisoflavones
(genistein was not included) was associated
with a substantial reduction in breast cancer
risk (72). A similar but more recent study
did not find significant differences in soy
protein intake or urinary excretion levels of
daidzein or genistein between breast cancer
cases and their controls in Shanghai; howev-
er, total isoflavonoid levels in urine were
lower in the breast cancer cases (73). Four
other studies also suggest that soy consump-
tion is not associated with a reduced risk of
breast cancer (74-76). These significant
inconsistencies may reflect differences in the
end points used for soy/genistein intake
(consumption of tofu or miso, or serum
isoflavone concentrations). They may also
suggest that high intake of genistein is not
the key factor behind low breast cancer
incidence in Asian countries. We recently
performed a meta-analysis ofall the epidemi-
ologic studies currently available. The results
indicate that high soy intake might reduce
the risk ofdeveloping premenopausal breast
cancer, but has no effect on postmenopausal
breast cancer risk (77).
Conclusionsfrom in vitro and in vivo
data. There appears to be a great disparity
among the findings of both animal and
human studies. Is genistein an anticancer or
a cancer-promoting agent? The answer may
very well be both. One ofthe most convinc-
ing explanations for the duality ofthis com-
pound lies in the experimental design-
specifically dosage. It is well documented
that the classical antiestrogen tamoxifen has
agonist properties when administered at low
doses and antagonistic properties when
administered at higher doses (78). Thus
studies showing antiproliferative effects
using genistein at high doses (> 1 pM) could
show similar antiestrogenic actions such as
those with tamoxifen. Indeed, many in vitro
studies conducted using human breast can-
cer cell lines indicate a biphasic effect of
genistein. Interestingly, a study byAnderson
et al. (27) showed that at low doses, genis-
tein exerted estrogen-like beneficial effects
on bone tissue in ovariectomized rats, where-
as at high concentrations these estrogenic
effects were not seen. Given the potentially
biphasic effects of genistein, it is important
to determine what the relevance of these
concentrations is to women on soy-supple-
mented diets. Reports in women consuming
large amounts ofsoy products indicate con-
centrations ofup to 0.25 mg/kg genistein in
the plasma and urine (10). It appears from
in vitroand in vivoanimal studies that phar-
macologic doses may be required for the
breast cancer preventative effects seen with
genistein. It is possible that in humans a
diet containing foods high in genistein will
never reach the levels that are able to effec-
tively inhibit mammary tumorigenesis in
vitro and in animal models. However, this
conclusion is contradicted by our meta-
analysis, which showed a protective effect of
high soy intake among premenopausal
women (77), and in animal studies in which
rats were given a physiologic dose of genis-
tein prepubertally, resulting in reduced
mammary tumor incidence (79).
Genistein and Nonestrogenic
Pathways of Action
The antiproliferative effects seen with phar-
macologic doses ofgenistein are unlikely to
be mediated by the ER. Instead, they are
probably due to other biological effects of
genistein. For example, genistein is a specific
inhibitor of protein tyrosine kinase (PTK)
(11). Genistein induces a reversible G2M cell
cycle arrest, which may be related to its abili-
ty to inhibit PTK (80,81). Other important
mechanisms bywhich genistein may exert its
antiproliferative effects are through its ability
to inhibit both topoisomerase II and angio-
genesis (12,13). Additionally, it has recently
been suggested that the growth inhibitory
effects of genistein may be due to modula-
tions in transforming growth factor-3 signal
transduction (82).
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PTKs regulate a number of growth fac-
tor receptor signal transduction pathways,
which can become oncogenic when altered.
Therefore, a potent inhibitor of PTK could
counteract this oncogenic activity. One
widely studied PTK-associated growth-pro-
moting pathway is the epidermal growth
factor pathway. Increased expression of the
epidermal growth factor receptor (EGFR) in
breast cancer cells has been associated with
accelerated growth and metastasis and is an
indicator of poor prognosis (83). EGFR
contains a PTK domain and upon activation
and dimerization of the receptor, phospho-
rylation of the PTK domain occurs. This
results in signaling events to downstream
effector molecules, ultimately leading to an
inhibition ofapoptosis. It has been postulat-
ed that genistein's ability to inhibit the PTK
of EGFR (or other potentially oncogenic
proteins) may be an important mechanism
mediating its observed antiproliferative
effects in breast cancer. In support ofthis, a
number ofstudies have demonstrated genis-
tein's ability to inhibit both PTK and the
proliferation of a number of ER+ and ER-
breast cancer cell lines (84,85). An indica-
tion that genistein-induced inhibition of
PTK may be independent of ER-mediated
functions was shown by Schultze-Mosgau et
al. (85). The authors demonstrated that
pharmacologic doses ofgenistein inhibit the
PTK-dependent transcription of c-fos and
subsequent cellular proliferation in an ER-
human breast cancer cell line. Thus, the
antiproliferative effects appear to be due to
an inhibition ofPTK rather than an inhibi-
tion of ER signaling. Additionally, a study
by Uckun et al. (86) showed that targeting
nanomolar concentrations ofgenistein to the
EGFR-PTK complex by means of an
EGF-genistein conjugate resulted in a rapid
apoptotic effect and inhibition of in vitro
clonogenicity in human breast cancer cells.
Similar results were seen when targeting the
Src family ofPTK with an anti-CD19 anti-
body-genistein conjugate (87). As with the
EGF-genistein conjugate, this was effective
at increasing apoptosis and decreasing cell
growth at nanomolar concentrations.
Genistein's ability to inhibit tyrosine
phosphorylation not only allows for an inhi-
bition ofa proliferation ofcancer cells, but it
may also lead to an inhibition ofmetastasis.
It has been suggested that tyrosine phospho-
rylation of membrane proteins plays a criti-
cal role in the mediation of degradation of
the extracellular matrix, thus allowing for
cellular invasion (88). In a recent study,
Connolly et al. (89) attempted to reverse the
metastasis promoting effects of n-6 polyun-
saturated fatty acids (PUFAs) in intact nude
mice transplanted with ER- human breast
cancer cells (MDA-MB-435) by feeding the
animals soy protein. They found that soy
increased, rather than decreased, the size of
both primary tumors and lung micrometas-
tases in the high n-6 PUFA group. However,
the number of macrometastases was signifi-
cantly reduced by soy. These results suggest
that genistein/soy may promote mammary
tumor growth in the nude mouse model
both in ER+ (18) and ER- tumor cells (89)
but has both inhibitory and stimulatory
effects on various aspects of metastasis (89).
In addition, Li et al. (90) demonstrated that
genistein inhibits the secretion of matrix
metalloproteinase (proteinases which have
been implicated in invasion and metastasis)
in MDA-MB-435 breast cancercells.
It is important to note that pharmacolog-
ic doses are required for all ofthese non-ER-
mediated effects of genistein [concentration
that inhibits cell growth by 50% (IC50) > 1
pM], with the exception of the genistein
conjugates used by Uckun et al. (86,87).
Interestingly, Peterson et al. (84) demon-
strated that although genistein can induce
growth inhibition ofa number ofbreast can-
cer cell lines at pharmacologic doses (IC50
2.3-20 pglmL), these doses do not correlate
with PTK inhibition. Doses of 50 pg/mL
genistein were required to significantly
inhibit EGFR tyrosine phosphorylation.
Schultze-Mosgau et al. (85) showed similar
findings for EGFR in MDA-MB-468 breast
cancer cells. Genistein was able to inhibit the
growth ofthese cells at an IC50 of< 10 pM,
whereas PTK was inhibited at doses of 60
pM (86). Additionally, Peterson and Barnes
(84) showed that doses up to 20 pg/mL
genistein were insufficient to inhibit the
tyrosine phosphorylation of other PTKs
such as phospholipase Cy and Raf, whereas
doses up to 50 pg/mL did not inhibit tyro-
sine phosphorylation of MAPK or PI3K.
This is further supported by Koroma et al.
(80), who reported that in bovine aortic
endothelial cells, genistein doses of> 300 pM
were required to inhibit PTK, whereas
growth was inhibited at concentrations of <
30 pM. Thus, these data strongly suggest
that the antiproliferative effects of genistein
are not mediated through inhibition ofPTK.
However, although genistein does not
appear to be inhibiting EGFR (or other
PTKs that have been studied) at physiologic
doses, or even at pharmacologic doses associ-
ated with growth inhibition, this does not
preclude the possibility that genistein medi-
ates its growth-inhibitory effects through the
inhibition of other PTK-dependent path-
ways. It is possible that at lower pharmaco-
logic doses (those associated with genistein's
growth inhibitory effects) genistein targets an
as yet unidentified kinase or a kinase which
has not been examined within this context.
Additionally, kinase inhibitors specific for a
particular kinase can inhibit other kinases
when administered at extremely high doses.
This may be due to the similarities in struc-
ture ofthese inhibitors, given that many are
designed to target the adenosine triphosphate
(ATP) binding site ofPTKs. The possibility
ofgenistein mediating its growth-suppressive
effects through the inhibition ofan unknown
kinase at lower pharmacologic doses and
nonspecifically inhibiting other kinases at
high doses could explain the observed lack of
correlation between growth inhibition at
lower doses and PTK inhibition ofEGFR by
higherdosegenistein.
The Uckun studies (86,87) targeting
conjugated genistein into direct association
with PTK raise an important possibility. In
these studies conjugated genistein was able
to inhibit PTKat nanomolarconcentrations;
in the same experiments, genistein alone was
unable to achieve this even at micromolar
concentrations (> 10 pM for EGFR inhibi-
tion). However, when directed to PTK
genistein is effective at physiologic concen-
trations in the nanomolar range. Proposed
explanations for the efficacy of these genis-
tein conjugates at nanomolar concentrations
are increased delivery of genistein, direct
contact with PTK, and localization in close
proximity to ATP binding domains ofPTK,
thus possibly increasing the binding con-
stant. Nevertheless, despite a lack of under-
standing ofthe exact mechanism ofgenistein's
antiproliferative action, it is dear that at phar-
macologic doses genistein may be an impor-
tant inhibitor ofbreast cancercell growth and
may alter metastatic properties. Additionally,
it is possible that even at physiologic concen-
trations genistein has the potential to exert
anticancer properties through inhibition of
PTK, but lacks the ability to effectively reach
suchtargetmolecules.
liming of Genistein Exposure
and Mammary Tumorigenesis
In addition to dose, timingofadministration
may explain the apparent dual effects of
genistein. Throughout the life span, estro-
gens increase mammary cell proliferation,
but depending on the overall hormonal envi-
ronment, estrogens also activate expression
ofother factors that could induce differenti-
ation or affect mammary growth by other
means. Thus, estrogens can have a different
impact on the breast if the exposure occurs
in utero., during childhood, puberty, or preg-
nancy; premenopausally; or during post-
menopause (91). There is evidence that
genistein also has different effects on the
breastdepending on the timingofexposure.
We examined the effects of exposing
pregnant rats to genistein (at doses ranging
from 20 to 300 pg) on mammary gland
development and tumorigenesis among the
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offspring (22,92). The rationale for this
study was based on the fact that mice and
rats exposed to estradiol or other estrogenic
compounds in utero only, i.e., time ofexpo-
sure was restricted to the in utero period,
exhibit an increase in mammary tumorigene-
sis (93,94). Furthermore, epidemiologic data
suggest that high estrogen levels during preg-
nancy increase breast cancer risk among
daughters (95-97). Our results indicate that
in uteroexposure to genistein through a preg-
nant mother increases the risk to develop
7,12-dimethylbenz[a]anthracene (DMBA)-
induced mammary tumorigenesis in rats but
does not increase the number of tumors per
rat (multiplicity) (92). Thus in utero genis-
tein may act as an estrogen in the mammary
gland. Interestingly, a recent study found
that the free fraction ofestradiol in fetal cord
serum is 0.05% of that in adult human
serum (98). Nagel et al. (98) therefore postu-
lated that there may be an undefined mecha-
nism limiting the uptake of endogenous
estrogens. They go on to suggest that phytoe-
strogens may not be limited by this uptake
mechanism, which could result in increased
exposure to these exogenous estrogens during
prenatal life. This is speculative, however,
and needs to be further substantiated.
The mechanism mediating the effects of
in utero estrogen/genistein exposure on
mammary tumorigenesis may be related to
changes in mammary gland morphology. In
the mammary gland, terminal end buds
(TEBs) are the least mature ductal struc-
tures, containing multipotent stem cells, and
are the most susceptible to carcinogens.
With maturation, TEBs either differentiate
into alveolar buds (which comprise type I
and II lobules) or regress to terminal ducts.
During pregnancy, lobules I and II further
mature into type III lobules. In rats, and per-
haps also in humans, more differentiated
lobular structures give rise only to benign
tumors (99). Our data indicate that in ani-
mals exposed to estrogens or genistein in
utero, the number ofTEBs in the mammary
gland is increased and remains increased,
and the number ofterminal ducts and differ-
entiated alveolar buds is reduced, when com-
pared to animals exposed to vehicle control
in utero (22).
The findings indicating that in utero
exposure to genistein increases mammary
tumorigenesis in rats are in sharp contrast to
findings in Asian women. These women
consume high levels ofsoy products, includ-
ing during pregnancy, and their newborns
have high plasma levels ofphytoestrogens at
birth similar to their mothers' levels (100).
However, breast cancer risk is low among
Asian women. One explanation may be that
Asian women are exposed to high levels of
phytoestrogens throughout their lives,
whereas in our study rats received genistein
only in utero. Another explanation could be
that soy has many other components in
addition to genistein, and these components
may antagonize the estrogenic effects of
genistein in utero. This interpretation is sup-
ported by our unpublished study (101) in
which no changes in DMBA-induced mam-
mary tumorigenesis were noted in offspring
of rat dams who consumed varying levels of
soy protein during pregnancy.
The period when the breast is particular-
ly vulnerable to the effects of carcinogens is
between puberty and a first full-term preg-
nancy. During this time, there are a high
percentage of TEBs and many actively pro-
liferating cells in the breast. We (79) and
others (60,102,103) have studied the effects
of prepubertal genistein exposure on mam-
mary tumorigenesis induced by DMBA.
Studies by Lamartiniere et al. (60), Murrill
et al. (102), and Brown et al. (103) demon-
strated that postpartum (days 2, 4, and 6) or
prepubertal (days 16, 18, and 20) treatment
of rats with 5 mg genistein resulted in
increased latency and reduced the incidence
and multiplicity of breast tumors. We (79)
recently replicated these findings by admin-
istering 20 pg genistein between postnatal
days 7 and 21; this dose is closer to the
human exposure range. At day 21, the genis-
tein-exposed animals had a higher percentage
of TEBs and increased cellular proliferation
compared to control animals, but by day 50
the TEBs had differentiated to lobular struc-
tures, which were not susceptible to malig-
nant growth, and the glands exhibited less
cellular proliferation (60,102). Thus, genis-
tein administered after birth but before the
onset ofpuberty may, in the long term, have
a differentiating effect on mammary gland
ductal structures and may be chemopreven-
tive (60). It is also important to point out
that prepubertal genistein administration did
not alter puberty onset, although estradiol
exposure during the same time period effec-
tively advances puberty. The results ofstud-
ies in which genistein was administered in
utero or before puberty indicate that these
exposures can have significant but opposing
effects on the normal development ofTEBs
in the mammary gland and influence its sus-
ceptibility to carcinogenesis. Fritz et al.
(104) recently conducted a study in which
rats were exposed via diet to genistein from
conception (and throughout fetal life) to
postpartum day 21. This perinatal exposure
significantly reduced the multiplicity (num-
ber of tumors per animal) of DMBA-
induced mammary tumors but did not affect
the proportion of animals per group who
developed tumors (tumor incidence). Thus,
it appears that some ofthe adverse effects of
in utero genistein exposure on mammary
tumorigenesis can be partially reversed by pre-
pubertal exposure to the same phytoestrogen.
It is difficult to conceptualize why genis-
tein would have different effects on breast
cancer risk based on the timing ofexposure.
Do these findings suggest that genistein is
estrogenic in utero and antiestrogenic during
adolescence? In addition, is genistein also
antiestrogenic during the reproductive years
and estrogenic again postmenopausally? It is
more likely that genistein is always acting as
an estrogen if the level of exposure is main-
tained at a level low enough as to stimulate
only the ER. The differentiating effect on the
mammary gland with prepubertal genistein
exposure also occurs after prepubertal estradi-
ol exposure. For example, animal studies
indicate that neonatal and postpubertal expo-
sure to estrogens reduces subsequent mam-
mary tumorigenesis (105,106). Furthermore,
in human studies, high fat intake or high
body mass index at puberty, both of which
increase availability ofnongonadal estrogens,
are linked to reduced (not increased) breast
cancer risk (107,108). These data suggest
that high prepubertal estrogen levels may
effectively protect the breast from malignant
transformation, perhaps by inducing early
breast differentiation.
During the reproductive years, genistein
increases mammary gland proliferation, as is
evident in two human studies (23,24).
Animal studies also show that genistein
induces proliferation of the mammary
epithelial structures (18). However, there is
no evidence that genistein increases breast
cancer risk in premenopausal women; it may
modestly reduce it (77). Animal data suggest
that genistein may promote breast cancer
growth in ovariectomized mice (18); i.e., in
a postmenopausal breast cancer model. The
apparent difference in the effects ofgenistein
on breast cancer risk premenopausally and
postmenopausally may be explained by the
fact that the breasts of older women are
more likely to contain malignant cells as
compared to the breasts ofyounger women.
Although the proliferative effects ofgenistein
on postmenopausal women have not been
extensivelystudied, it is possible that genistein
induces proliferation of mammary cells in
both pre- and postmenopausal women.
However, in postmenopausal women, who
are more likely to have accumulated malig-
nancies than their younger counterparts,
genistein may stimulate the proliferation of
these malignant cells leading to the formation
ofbreast cancer. Therefore, genistein may not
be antiestrogenic premenopausally, but
rather, the mammary gland of younger
women may be less fertile ground for the
development ofcancer.
In conclusion, the differential effects of
genistein on breast cancer risk throughout
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life from in utero to the postmenopausal
period appear similar to those ofendogenous
estrogens, further supporting the role of
genistein as an estrogenic compound.
Conclusion
Based on data in the literature, it appears
that genistein can act as both an estrogen
and an antiproliferative agent. These effects
may be both dose and tissue dependent.
This is in agreement with data from studies
with other estrogenic compounds such as
tamoxifen (a partial estrogen receptor ago-
nist) and diethylstilbestrol (a potent ER
agonist). Additionally, the timing of expo-
sure may be critical in determining the car-
cinogenic/anticarcinogenic potential of
genistein. Gonadal and placental estrogen
production varies dramatically during a
woman's life span, as does the production of
other factors that regulate the breast. It is
plausible that genistein has different effects
on the breast in the presence ofhigh estro-
gen levels (such as during pregnancy), mod-
erate levels (such as during premenopausal
life), and low levels (such as during child-
hood and postmenopause).
It is clear from epidemiologic data that
Asian women living in Asia (where a diet
high in soy is consumed) have a decreased
risk for breast cancer. One possible explana-
tion for the apparent lack oftumor-promot-
ing effects ofgenistein in Asian populations
is that a lifetime exposure to genistein may
have a protective effect. It is also possible
that soy contains other factors besides genis-
tein that oppose the estrogenic effects of
genistein and actually reduce breast cancer
risk. Additionally, other environmental or
lifestyle factors may be more related to the
low breast cancer risk seen in this population
than soy/genistein consumption.
Although the evidence of the range of
genistein's effects is far from conclusive, it is
tempting for some in the scientific commu-
nity to tout genistein as a potential chemo-
preventive agent or alternative to hormone
replacement therapy. However, studies indi-
cating a potential cancer-promoting effect of
genistein should not be taken lightly.
Further studies must be done before the true
scope of genistein's actions can be under-
stood. Given the recent U.S. Food and Drug
Administration approval of an over-the-
counter soy supplement and recent media
reports touting this as an alternative to hor-
mone replacement therapy, the need for a
clearer understanding of the potential can-
cer-promoting effects of genistein is para-
mount. Fortunately, genistein continues to
be an active area of research interest, and
therefore an explanation for the dual nature
ofgenistein may not be too far away.
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